The HELLS Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the HELLS gene, providing a comprehensive loss-of-function model for epigenetic regulation studies. This pooled knockout resource avoids clonal artifacts and represents a broad spectrum of editing outcomes, making it ideal for functional genomics applications.
The HEK293T host cell line, derived from human embryonic kidney cells, constitutively expresses SV40 large T antigen, ensuring exceptional transfection efficiency and episomal replication of plasmids. This feature, combined with robust growth and ease of manipulation, establishes HEK293T as a premier system for protein expression, lentiviral packaging, and transient genetic modifications, enabling seamless integration of complementary assays alongside knockout analysis.
HELLS encodes a SNF2-like chromatin remodeling ATPase that orchestrates heterochromatin maintenance. It directly interacts with DNMT3B, HDAC1/2, and G9a to promote DNA methylation and histone H3K9me3 at pericentromeric repeats and retrotransposons, enforcing transcriptional silencing. HELLS is activated by upstream E2F and MYC factors and functions downstream of Wnt/??-catenin/TCF signaling, coupling proliferation signals to epigenetic fidelity. Additionally, HELLS associates with ??-catenin, DNMT1, and the NuRD complex, integrating chromatin modification and signaling.
Loss of HELLS in HEK293T cells disrupts maintenance of DNA methylation patterns and heterochromatic silencing, mimicking key epigenetic defects observed in ICF4 syndrome and cancers such as colorectal, lung, and breast carcinomas. This model allows precise dissection of HELLS-dependent pathways, including its role in stabilizing Wnt/??-catenin signaling outputs and cell cycle progression, without interference from related remodeling factors. Consequently, the knockout serves as a platform to investigate genome stability and oncogenic mechanisms.
These polyclonal knockout cells support a wide range of techniques: bisulfite sequencing for methylation mapping, ChIP-qPCR for histone modifications and protein occupancy, RNA-seq for retrotransposon activation analysis, and co-immunoprecipitation for probing HELLS-containing complexes. Functional assays such as proliferation, colony formation, and flow cytometry permit assessment of cell growth defects. Applications span epigenetic drug testing, cancer biology, and disease modeling. For further details, contact Ascent Research.
